我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
100.0%
暂无批准数据
- BioCorRx Inc. announced the issuance of a new U.S. patent strengthening its intellectual property portfolio for biodegradable naltrexone implant technologies. - The company's investigational BICX104 implant is designed to provide controlled naltrexone delivery and commenced a new clinical study in January 2026 supported by NIDA. - The patent expands BioCorRx's growing portfolio that includes international patents covering naltrexone implants for various therapeutic applications including weight management programs. - The development addresses significant unmet needs in treating opioid use disorder, which affects approximately 5.7 million Americans according to 2023 national survey data.
